Mutations in both RAD51C and RAD51D seem to primarily increase risk for ovarian cancer, and are present at greater frequency in women with breast cancer in the context of familial ovarian cancer than in women with breast cancer in the absence of a family history of ovarian cancer, such that there may be no increased risk for breast cancer when there are no reported cases of ovarian cancer in the family (Loveday et al, 2011; Pelttari et al, 2011). Here, RAD51D is linked to ovarian cancer.